title: Acute Erosive Esophagitis As a Rare Complication of Severe Pediatric Diabetes Ketoacidosis.
authors.affiliation: *Division of Pediatric Endocrinology†Division of Pediatric Gastroenterology‡Division of Pediatric Critical Care, Department of Pediatrics, Rhode Island Hospital/Hasbro Children's Hospital, The Warren Alpert Medical School of Brown University, Providence.
authors.forename: Serife
authors.initials: S
authors.lastname: Uysal
authors.forename: Basavaraj
authors.initials: B
authors.lastname: Kerur
authors.forename: Jason M
authors.initials: JM
authors.lastname: Shapiro
authors.forename: Linda K
authors.initials: LK
authors.lastname: Snelling
authors.forename: Jose Bernardo
authors.initials: JB
authors.lastname: Quintos
mesh_terms: D000293:Adolescent; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003680:Deglutition Disorders / Q000209:etiology / Q000517:prevention & control; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D016883:Diabetic Ketoacidosis / Q000150:complications* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D005764:Gastroesophageal Reflux / Q000150:complications; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012720:Severity of Illness Index; D013392:Sucralfate / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D013392:Sucralfate